Core Viewpoint - The flu-related stocks experienced a significant surge on October 21, with notable increases in companies such as Te Yi Pharmaceutical, Jinshi Yao, and Hualan Vaccine, driven by rising flu activity in southern China and predictions of an earlier flu season this year [1][4]. Group 1: Stock Performance - Te Yi Pharmaceutical reached a trading limit with a price of 10.27, reflecting a 9.96% increase [2] - Jinshi Yao saw a price increase to 11.73, marking a 15.11% rise [2] - Hualan Vaccine's stock rose to 22.15, showing an 11.87% increase [2] - New Ganjing's stock price increased to 23.72, with a rise of 11.41% [2] - Other companies like Hengdi Pharmaceutical and Xiangrikui also followed the upward trend [1]. Group 2: Flu Activity and Predictions - The China CDC reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season this year [4] - Experts noted that the predominant flu strain this year is H3N2, differing from last year's H1N1 strain, which may lead to lower immunity levels in the population [5]. Group 3: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for individuals to get vaccinated between September and November [8] - The flu vaccine needs to be administered annually due to the rapid mutation of the virus, ensuring protection against the current year's strains [8][9]. - High-risk groups, including children under 5, the elderly, and individuals with chronic health conditions, are advised to prioritize vaccination [12].

Group 1 - The core viewpoint of the article highlights a significant rise in flu-related stocks, with companies like Te Yi Pharmaceutical hitting the daily limit, and others like Jinshi Yao, Hualan Vaccine, and Xin Ganjing seeing increases of over 10% [1][2] - The flu activity in southern China is on the rise, with experts predicting an earlier flu season this year compared to last, and the circulating strain being different from the previous year [2][3] - The predominant strain this year is H3N2, which may lead to lower immunity in the population compared to last year's H1N1 strain, necessitating increased attention [4][5] Group 2 - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for vaccination between September and November to ensure effective immunity before peak season [6][7] - The article discusses the differences between trivalent and quadrivalent flu vaccines, noting that while quadrivalent vaccines cover an additional strain, the practical difference in effectiveness is minimal [10] - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to prioritize flu vaccination [12]

Core Viewpoint - The article highlights the rising flu activity in southern China, with predictions of an earlier flu season this year compared to last, primarily driven by the different circulating strain, H3N2, which the public has lower immunity against [2][3]. Group 1: Flu Activity and Strain Information - The current flu season is characterized by the predominance of the H3N2 strain, contrasting with last year's H1N1 strain, indicating a need for heightened awareness due to lower public immunity [3]. - Clinical symptoms of H3N2 include high fever, cough, sore throat, body aches, fatigue, and headache, which are similar to other flu strains [3]. Group 2: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with the recommended vaccination period being from September to November to ensure immunity before peak season [5]. - Annual vaccination is necessary due to the rapid mutation of flu viruses, which may differ from year to year, thus requiring updated protection [6]. - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to receive vaccinations promptly [10]. Group 3: Vaccine Types and Administration - The available flu vaccines in China include inactivated (split) vaccines (trivalent/quadrivalent), inactivated (subunit) vaccines (trivalent/quadrivalent), and live attenuated vaccines (trivalent, nasal spray) [8]. - The difference between trivalent and quadrivalent vaccines lies in the number of virus strains they protect against, with quadrivalent covering an additional B strain, although the practical effectiveness may not differ significantly [8].

证券日报网讯 10月15日晚间，亨迪药业（301211）发布公告称，公司于2025年10月15日召开2025年第 二次职工代表大会，经与会职工代表审议，同意选举陈吉人先生为公司第二届董事会职工代表董事。 ...

南财智讯10月15日电，亨迪药业公告，公司董事肖云华先生因个人原因辞去董事及董事会战略委员会委 员职务，辞职后不再担任公司任何职务。公司于2025年10月15日召开职工代表大会，选举陈吉人先生为 新的职工代表董事，任期至第二届董事会届满。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-044 湖北亨迪药业股份有限公司 关于董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 三、备查文件 1、公司 2025 年第二次职工代表大会会议决议。 特此公告。 湖北亨迪药业股份有限公司 2025 年 10 月 15 日 湖北亨迪药业股份有限公司董事会于近日收到公司董事肖云华先生的书面 辞职报告。肖云华先生因个人原因，申请辞去公司董事职务，同时一并辞去公司 董事会战略委员会职务，辞去上述职务后肖云华先生将不在公司担任任何职务。 公司对肖云华先生任职期间的勤勉尽责以及对公司做出的贡献表示衷心的感谢。 肖云华先生作为第二届董事会董事的原定任期为2023年6月21日起至2026 年 6 月 21 日。根据《公司法》及《公司章程》等有关规定，肖云华先生辞任董 事不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运 作，其辞职报告自送达公司董事会之日起生效。 截至本公告披露日，肖云华先生未持有公司股份，不存在应当履行而未履行 的承诺事项。辞去董事职务后将继 ...

证券日报网讯 10月13日晚间，亨迪药业发布公告称，公司于2025年9月2日召开第二届董事会第十五次 会议、2025年9月18日召开了2025年第二次临时股东大会，审议通过了《关于变更公司注册资本、修订 公司章程并办理工商变更登记的议案》，同意公司变更注册资本及修订《公司章程》并由董事会指定相 关人员办理工商登记。 （文章来源：证券日报） ...

湖北亨迪药业股份有限公司 关于公司完成工商变更登记并换发《营业执照》的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2025 年 9 月2日召开第二届董事会第十五次会议、2025年9月18日召开了2025 年第二次临时股东大会，审议通过了《关于变更公司注册资本、修订 公司章程并办理工商变更登记的议案》，同意公司变更注册资本及修 订《公司章程》并由董事会指定相关人员办理工商登记,具体内容详 见公司刊载于中国证监会指定信息披露网站巨潮资讯网 (www.cninfo.com.cn)的相关公告。 公司于近日完成了相关工商变更登记手续及公司章程备案手续， 并取得了荆门市市场监督管理局换发的营业执照，本次变更后公司相 关工商登记信息如下： 一、变更后的营业执照基本情况 证券代码：301211 证券简称：亨迪药业 公告编号：2025-043 6、成立日期：1995 年 12 月 29 日 7、住 所：荆门市掇刀区杨湾路 122 号 8、经营范围： 许可项目：药品生产，药品进出口，药品委托生产，药品互联网 信息服务。（ ...

（文章来源：证券日报） 证券日报网讯亨迪药业9月23日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东户数 为18196户。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-042 湖北亨迪药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 1、本次股东大会没有出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况； 3、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席的情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 9 月 18 日（星期四）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 9 月 18 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体 时间为：2025 年 8 月 18 日 9:15—15:00 期间的任意时间。 2、会议召开方式：本次股东大会采取现场投票与网络投票相结 合的方式。 3、会议召开地点：湖北省荆门市杨湾路 122 号公司会议室。 特别提示： 4、会议召集人：公司董事会。 5、 ...